Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20+, B-cell Lymphomas”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00005601
What this trial is testing

Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Alliance for Clinical Trials in Oncology 58
Early research (Phase 1)Ended earlyNCT06295549
What this trial is testing

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital with Nanjing Medical University 11
Large-scale testing (Phase 3)Study completedNCT01459887
What this trial is testing

Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma
Shanghai CP Guojian Pharmaceutical Co., Ltd. 278
Testing effectiveness (Phase 2)Ended earlyNCT02384954
What this trial is testing

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Who this might be right for
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Altor BioScience 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT03888105
What this trial is testing

Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

Who this might be right for
B-cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals 515
Testing effectiveness (Phase 2)Study completedNCT00607854
What this trial is testing

Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

Who this might be right for
Diffuse Large B-Cell LymphomaMantle Cell Lymphoma
University Hospital, Bordeaux 31
Testing effectiveness (Phase 2)Study completedNCT02933320
What this trial is testing

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

Who this might be right for
B-cell LymphomaChronic Lymphocytic LeukaemiaWaldenström Macroglobulinemia
Cancer Research UK 14
Early research (Phase 1)UnknownNCT03271515
What this trial is testing

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Who this might be right for
LeukemiaLymphoma
Beijing Doing Biomedical Co., Ltd. 20
Testing effectiveness (Phase 2)Study completedNCT01087424
What this trial is testing

Mini-CHOP and Rituximab in Patients Aged Over 80 Years

Who this might be right for
Diffuse Large B-Cell Lymphoma
Lymphoma Study Association 150
Testing effectiveness (Phase 2)Study completedNCT03664635
What this trial is testing

MB-CART20.1 Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaB-cell Lymphoma Refractory+1 more
Miltenyi Biomedicine GmbH 10
Testing effectiveness (Phase 2)UnknownNCT04304040
What this trial is testing

MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

Who this might be right for
B-cell Lymphoma RecurrentB-cell Lymphoma Refractory
Beijing InnoCare Pharma Tech Co., Ltd. 43
Testing effectiveness (Phase 2)WithdrawnNCT00003663
What this trial is testing

Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Study completedNCT00032019
What this trial is testing

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Alliance for Clinical Trials in Oncology 78
Large-scale testing (Phase 3)Ended earlyNCT01287741
What this trial is testing

Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 1,418
Very early researchUnknownNCT04169932
What this trial is testing

The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed and Refractory B Cell LymphomaNon-Hodgkin Lymphoma
Shanghai Longyao Biotechnology Inc., Ltd. 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05421663
What this trial is testing

JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC 166
Early research (Phase 1)Study completedNCT01569750
What this trial is testing

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

Who this might be right for
CD20-positive B-cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC 33
Testing effectiveness (Phase 2)Study completedNCT00080886
What this trial is testing

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
University of Nebraska 68
Early research (Phase 1)Ended earlyNCT04049383
What this trial is testing

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed RemissionAcute Lymphoblastic Leukemia Recurrent+3 more
Medical College of Wisconsin 5
Early research (Phase 1)Study completedNCT02924402
What this trial is testing

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Who this might be right for
B-cell Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
Xencor, Inc. 154
Next Page